Growth Driven by Rising Global Rates of Osteoarthritis and Obesity, According to Millennium Research Group
January 28, 2013—Toronto—
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the patient pool for hyaluronic acid (HA) viscosupplementation will continue to expand globally, due to rising rates of osteoarthritis and obesity, leading to moderate growth in the global HA viscosupplementation market to nearly $2.5 billion by 2017.
The most significant treatment trend will continue to be the shift to premium-priced shorter treatment regimens, which offer more convenience for the patient and increase patient compliance with treatment. This trend will occur worldwide. While 5-injection treatments are still the leading choice for patients globally, the number is skewed by Japan, where more than 80 percent of such procedures were performed in 2011. One- and 3-injection treatments will continue to rise as a proportion of total treatments.
While HA viscosupplementation treatments are used primarily in the knee, there will be a shift toward using this treatment for other joints in the body, as physicians become more comfortable performing the procedure on non-knee areas. Manufacturers are investing in non-knee clinical trials to provide support for this shift.
“Despite the diverse competitive landscape for these products, two companies have captured over half the global market,” said MRG Analyst Kristina Vidug. “While they both sell in all three major regions, Seikagaku is strongest in Asia Pacific, while Sanofi dominates the United States market.”
Companies that compete on price, introduce a product that is specific to a non-knee indication or release a single-injection product will be most successful in this market through 2017.
Learn more about this Medtech 360 Report
Global Markets for Hyaluronic Acid Viscosupplementation 2013
Includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for HA viscosupplementation in the United States, Europe (France, Germany, Italy, Spain, and the United Kingdom), and the Asia Pacific and emerging markets (Australia, Brazil, China [Mainland China and Hong Kong], India, Japan, South Korea and Taiwan).